This talk will present phase I clinical data with RBI-4000, an improved srRNA vector encoding the rabies virus glycoprotein and encapsulated in a novel lipid nanoparticle. Demonstrating the high therapeutic index of next generation srRNA vectors in humans, the feasibility of both low dose and single dose administration, with sustained immune responses that are comparable or longer lasting than a commercial inactivated viral vaccine. In addition, data will be presented to highlight the potential of srRNA for applications beyond vaccines.